The popularity of the mass spectrometry industry remains unchanged and is revolutionizing precision medicine.
Aptbiotech (Chinese: 中科新生命), focused on mass spectrometry-based multi-omics applied to precision medicine, completed a Series B round of financing worth hundreds of millions of CNY. The funding round was led by Legend Capital (Chinese: 君联资本). Haoyue Capital (Chinese: 浩悦资本) served as the exclusive financial advisor.
This financing round will accelerate product R&D, market expansion, and data-driven precision medicine development.
Founded in 2004, Aptbiotech's predecessor was the Proteome Research and Analysis Center of Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences. It was one of the earliest enterprises to participate in international HLPP and HPPP projects.
Aptbiotech has established four technical platforms: a large-scale multi-omics analysis platform, biological drugs’ preclinical research and pilot production platform, mass spectrometry in clinical diagnosis platform and an AI and big data platform. As a company providing mass spectrometry solutions in China, Aptbiotech is dedicated to constructing the life and health industry chain and has published hundreds of papers in high-level SCI journals. The company integrates proteome, metabolome, clinical diagnosis and treatment, and pharmaceutical R&D data to provide a precise platform for the perfect transformation from basic research to clinical practice. Its proprietary Laboratory Information Management System (LIMS) strengthens laboratory quality monitoring and quality management to ensure the efficiency and security of customer data.
The main competitors of Aptbiotech are Calibra (Chinese: 凯莱谱), Baichen Medical (Chinese: 佰辰医疗) and Ruikang Bio (Chinese: 睿康生物).